SCHEMBL18257983

SCHEMBL18257983

CC1CC(=O)c2ccc(Cl)nc2C1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 11/20 0.54
RAB9A P51151 4/20 0.46
ALDH1A1 P00352 4/20 0.46
NPC1 O15118 3/20 0.46
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
MAOB P27338 3/20 0.45
POLB P06746 1/20 0.45
STAT1 P42224 1/20 0.42
KMT2A Q03164 1/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4170816 0.81 GRM5 (0.53) GRM5RAB9AALDH1A1NPC1KDM4E
SCHEMBL4430798 0.76 TSHR (0.51) ALDH1A1KDM4ESMN1; SMN2HPGDMAOB
SCHEMBL13998647 0.74 HTR2A (0.40) GRM5KMT2A
SCHEMBL23667196 0.73 MAP4K1 (0.39) GRM5SMN1; SMN2MAOBLMNA
SCHEMBL23667593 0.73 MAP4K1 (0.39) GRM5SMN1; SMN2MAOBLMNA
SCHEMBL25832091 0.72 GRM5 (0.39) GRM5RAB9AALDH1A1NPC1KDM4E
SCHEMBL21223432 0.72 GRM5 (0.39) GRM5ALDH1A1KDM4EHPGDMAOB
SCHEMBL31069650 0.72 GRM5 (0.39) GRM5ALDH1A1KDM4EHPGDMAOB
SCHEMBL9955316 0.72 GRM5 (1.00) GRM5RAB9AALDH1A1NPC1KDM4E
SCHEMBL9835747 0.70 GRM5 (0.51) GRM5RAB9AALDH1A1NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220125780-A1 SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS AURIGENE ONCOLOGY LIMITED (IN) 2022-04-28 US disclosed
US-11229636-B2 Substituted tetrahydroquinolinone compounds as ROR gamma modulators AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-01-25 US disclosed
EP-3845526-A1 METHOD FOR THE PREPARATION OF TETRAHYDROQUINOLINONE COMPOUNDS HAVING ROR-GAMMA MODULATING ACTIVITY Aurigene Discovery Technologies Limited (IN) 2021-07-07 EP disclosed
US-20210113551-A9 SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2021-04-22 US disclosed
EP-3294713-B1 SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECH LTD (IN) 2021-02-17 EP disclosed
US-20180200247-A1 Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-07-19 US disclosed
US-20180200247-A1 Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-07-19 US disclosed
WO-2016185342-A1 SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2016-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11229636-B2 Substituted tetrahydroquinolinone compounds as ROR gamma modulators RORC, RORA, RORB GRM5 475/4885RAB9A 736/4885ALDH1A1 235/4885
US-20180200247-A1 Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators RORC, RORA, RORB GRM5 475/4885RAB9A 736/4885ALDH1A1 235/4885
US-20210113551-A9 SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS RORC, RORA, RORB GRM5 475/4885RAB9A 736/4885ALDH1A1 235/4885
US-20220125780-A1 SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS RORC, RORA, RORB GRM5 475/4885RAB9A 736/4885ALDH1A1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.